MP03-07 IMPACT OF PRIOR INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER ON THE EFFICACY OF PEMBROLIZUMAB IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA

Abstract

You have accessJournal of UrologyCME1 May 2022MP03-07 IMPACT OF PRIOR INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER ON THE EFFICACY OF PEMBROLIZUMAB IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA Rikiya Taoka, Takashi Kobayashi, Yu Hidaka, Hiroyasu Abe, Satoshi Morita, Osamu Ogawa, Hiroyuki Nishiyama, Hiroshi Kitamura, and Mikio Sugimoto Rikiya TaokaRikiya Taoka More articles by this author , Takashi KobayashiTakashi Kobayashi More articles by this author , Yu HidakaYu Hidaka More articles by this author , Hiroyasu AbeHiroyasu Abe More articles by this author , Satoshi MoritaSatoshi Morita More articles by this author , Osamu OgawaOsamu Ogawa More articles by this author , Hiroyuki NishiyamaHiroyuki Nishiyama More articles by this author , Hiroshi KitamuraHiroshi Kitamura More articles by this author , and Mikio SugimotoMikio Sugimoto More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002515.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: This study aimed to determine whether prior intravesical bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer (NMIBC) affects the treatment outcomes of pembrolizumab in patients with urothelial carcinoma (UC). METHODS: In a multicenter retrospective study conducted under the Japan Urological Oncology Group framework, the clinicopathological data of 755 patients with metastatic, chemo-resistant UC who received pembrolizumab were retrospectively reviewed. The best overall response and overall survival (OS) from the initiation of pembrolizumab were analyzed concerning the BCG usage using propensity score matching (PSM). The propensity score was estimated using a logistic regression model with four covariates, namely, PS, metastatic site, pretreatment Hb level, and NLR. (Kobayashi T, et al. Cancer Sci. 2021). RESULTS: A total of 155 (20.5%) patients had a history of NMIBC treatment, of which 97 (12.8%) had received intravesical BCG therapy. When compared to patients without a NMIBC history (median 9.97 months), the OS in patients with a NMIBC history but not BCG (14.49 months, HR 0.68 [0.45–1.12], P=0.061) or those with a NMIBC history and BCG (12.13 months, HR 0.87 [0.64–1.17], P=0.356) were not significantly different. This tendency was robust after 1:1 or 1:2 PSMs. The objective response rate (ORR, 32.1% vs. 27.5%, P=0.606) and disease control rate (DCR, 56.6% vs. 45.1%, P=0.241) of the 58 patients with a NMIBC history but not BCG did not differ from those of 58 matched patients without a NMIBC history. The ORR in BCG-treated patients was significantly lower than that in those without a NMIBC history (19.8% vs. 33.3%, P=0.042), whereas DCR between the two groups did not differ significantly (55.8% vs. 54.4%, P=0.855). CONCLUSIONS: Our risk-adjusted analyses revealed that intravesical BCG therapy did not affect the treatment outcomes of pembrolizumab in metastatic UC patients. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e22 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Rikiya Taoka More articles by this author Takashi Kobayashi More articles by this author Yu Hidaka More articles by this author Hiroyasu Abe More articles by this author Satoshi Morita More articles by this author Osamu Ogawa More articles by this author Hiroyuki Nishiyama More articles by this author Hiroshi Kitamura More articles by this author Mikio Sugimoto More articles by this author Expand All Advertisement PDF DownloadLoading ...